Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

251
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
251
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

477
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
477

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Decoy oligonucleotide technology in cancer therapy: molecular mechanisms, challenges, and translational potential.

Medical oncology (Northwood, London, England)·2026
Same author

Injectable in-situ Forming Lipid Liquid Crystal for Long-acting Fluocinolone Release in Posterior Ocular Therapy: In-vitro and In-vivo Evaluations.

Pharmaceutical research·2026
Same author

Exploring the Potential of Calebin-A in Targeting Obesity-Related Genes and Pathways.

Journal of cellular and molecular medicine·2026
Same author

Superoxide Dismutase-Centered Modulation by Curcumin in Cardiovascular Diseases: Mechanistic Insights and Translational Implications.

Journal of cellular and molecular medicine·2026
Same author

Comparison of Chitosan-Poloxamer Nanoparticles and Poloxamer-based In-Situ Forming Gel for Nose-to-Brain Delivery of Cetrorelix: In Vitro and Pharmacokinetic Studies in Rats.

AAPS PharmSciTech·2026
Same author

Evaluating a health education intervention to improve pill swallowing for trainee doctors, nurses, physicians' assistants and pharmacists in Europe, the Middle East and Asia - KidzMed Goes Global.

Currents in pharmacy teaching & learning·2026

Related Experiment Video

Updated: Aug 24, 2025

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications
08:19

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications

Published on: November 17, 2015

18.0K

Solid lipid nanoparticles: a promising tool for insulin delivery.

Fatemeh Mohammadpour1, Hossein Kamali2,3, Leila Gholami4

  • 1Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

Expert Opinion on Drug Delivery
|October 26, 2022
PubMed
Summary

Solid Lipid Nanoparticles (SLNs) offer a promising, safe, and biocompatible method for insulin delivery, potentially improving therapeutic efficacy. Further research is needed to fully realize their clinical application as advanced insulin delivery vehicles.

Keywords:
Insulindiabetesdrug deliverysolid lipid nanoparticlestherapeutic agents

More Related Videos

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

9.0K
Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
09:41

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

23.5K

Related Experiment Videos

Last Updated: Aug 24, 2025

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications
08:19

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications

Published on: November 17, 2015

18.0K
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

9.0K
Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
09:41

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

23.5K

Area of Science:

  • Nanotechnology in drug delivery
  • Biopharmaceutical sciences
  • Metabolic disease research

Background:

  • Insulin is crucial for metabolic regulation but current delivery methods lack natural release profiles.
  • Optimizing insulin carriers remains a significant challenge in achieving effective therapeutic outcomes.
  • Conventional insulin delivery systems fail to replicate endogenous insulin release patterns.

Approach:

  • This review examines Solid Lipid Nanoparticles (SLNs) as a potential solution for insulin delivery.
  • SLNs are evaluated for their nontoxicity, biocompatibility, and formulation simplicity.
  • Emphasis is placed on the biopharmaceutical aspects of insulin-loaded SLNs.

Key Points:

  • Solid Lipid Nanoparticles (SLNs) demonstrate safety and versatility for insulin encapsulation.
  • SLNs can enhance the efficacy and pharmacokinetic profile of delivered insulin.
  • The biopharmaceutical characteristics of insulin-loaded SLNs require further in-depth investigation.

Conclusions:

  • SLNs present a viable platform for improved insulin delivery systems.
  • Further research is essential to fully establish SLNs for clinical insulin therapy.
  • Optimizing SLNs holds promise for overcoming limitations of traditional insulin delivery methods.